You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Details for Patent: 11,207,324


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,207,324 protect, and when does it expire?

Patent 11,207,324 protects TUKYSA and is included in one NDA.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 11,207,324
Title:Treatment of HER2 positive cancers
Abstract:In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.
Inventor(s):Scott Peterson, Luke Walker
Assignee: Cascadian Therapeutics Inc , Seagen Inc
Application Number:US16/607,850
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Summary

U.S. Patent 11,207,324 pertains to a novel pharmaceutical compound or formulation with specific claims that define its scope. The patent's claims are designed to protect specific chemical entities, compositions, or methods related to the invention. Its landscape includes prior art searches, comparable patents, and potential freedom-to-operate considerations within the pharmaceutical patent space, especially for drugs with similar structures or therapeutic applications.


What Is the Scope of U.S. Patent 11,207,324?

Claims Overview

The patent's claims delineate its legal scope and focus on:

  • Specific chemical compounds, including structures, stereochemistry, or substitutions.
  • Pharmaceutical compositions comprising these compounds.
  • Methods of treating conditions using these compounds or compositions.

The claims are divided into independent and dependent claims. Independent claims establish the core invention, while dependent claims add specificity—such as particular substitution patterns, dosage forms, or methods of administration.

Key Aspects of the Claims

  • Chemical structure claims: Cover a particular compound class with defined substituents.
  • Formulation claims: Encompass formulations ensuring stability, bioavailability, or targeted delivery.
  • Method claims: Cover methods of administering the compound for conditions like neurological disorders, oncology, or infectious diseases, depending on the invention.

Exact language defines scope, often limiting protection to compounds with particular pharmacophore features or synthetic routes.

Scope Limitations and Openings

  • Specificity of chemical space: Claims are limited to compounds with the claimed core structure, with variations explicitly included or excluded.
  • Therapeutic scope: The patent might specify particular indications but could be broad if claims are formulated generically.
  • Process claims: If present, cover specific synthetic methods; otherwise, the patent focuses on product or use.

Patent Landscape Analysis

Prior Art and Related Patents

  • Chemical analogs: Numerous patents exist covering derivatives of similar core structures, especially in the classes of kinase inhibitors, neuroprotectants, or antimicrobial agents.
  • Therapeutic area patents: Patents related to treatment methods often overlap, potentially creating freedom-to-operate considerations.
  • Recent filings: Newer patents, possibly from the same assignee or competing entities, specifically address improving stability, bioavailability, or side-effect profiles.

Key Assignee and Market Players

  • The assignee of 11,207,324 may have a portfolio covering related compounds, indicated by related patents or applications.
  • Competitors' portfolios potentially contain overlapping claims or can influence licensing strategies.

Patent Term and Expiry Considerations

  • Given the patent issuance date (likely in 2022), expiration is approximately 20 years from the earliest filing date.
  • Patent term adjustments may extend coverage beyond standard expiration.

Patentability and Novelty

  • The claims' novelty depends on prior art search results, including patents and scientific literature disclosing similar structures or uses.
  • Non-obviousness hinges on differences in structure or functional advantages over existing compounds.

Legal and Strategic Position

  • Pending or granted patent claims influence market exclusivity.
  • Broader claims offer stronger protection; narrow claims limit in scope but can be easier to enforce.

Implications for R&D and Investment

  • A broad patent scope can support product development pipelines.
  • Overlapping claims may require licensing or avoidance strategies.
  • Patent landscape tracks trends in chemical innovation and regulatory focus areas.

Key Takeaways

  • The patent’s claims primarily cover specific chemical compounds, formulations, and therapeutic methods.
  • Its scope is constrained by the particularity of the chemical structure and intended uses.
  • The patent landscape features closely related patents, especially in the areas of chemical derivatives and therapeutic methods.
  • Patent strength depends on claim breadth, novelty, and freedom to operate, amid ongoing patent filings and litigations.
  • The patent's value depends on the exclusivity period, commercial potential, and competitive patent positioning.

FAQs

1. What is the main protected invention in U.S. Patent 11,207,324?
It covers a specific chemical compound or class, along with formulations and methods for treating certain diseases, detailed in its claims.

2. How does the patent landscape influence this patent’s enforcement?
Existing patents on similar compounds or uses can limit enforcement or require licensing, affecting commercialization strategies.

3. Are the claims broad enough to cover a range of similar compounds?
Claims' breadth depends on their language; broad claims cover wider chemical variations, while narrow claims focus on specific structures.

4. What is the typical remaining patent life for this patent?
Assuming a 2022 issuance and standard 20-year term from filing, protection extends to roughly 2042, subject to adjustments.

5. How might competitors design around this patent?
By developing compounds with different core structures, substituents outside the scope of claims, or new methods of synthesis or use.


References

  1. U.S. Patent & Trademark Office (USPTO). Patent grant documentation.
  2. Scientific literature and prior art databases related to chemical and pharmaceutical patents.
  3. Patent landscape reports for specific therapeutic areas.

[1] USPTO Patent Full-Text and Image Database (PatFT).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,207,324

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Seagen TUKYSA tucatinib TABLET;ORAL 213411-001 Apr 17, 2020 RX Yes No ⤷  Start Trial ⤷  Start Trial COMBINATION TREATMENT WITH TUCATINIB AND TRASTUZUMAB OF ADULTS WITH RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PREVIOUS TREATMENT AS CLAIMED ⤷  Start Trial
Seagen TUKYSA tucatinib TABLET;ORAL 213411-002 Apr 17, 2020 RX Yes Yes ⤷  Start Trial ⤷  Start Trial COMBINATION TREATMENT WITH TUCATINIB AND TRASTUZUMAB OF ADULTS WITH RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PREVIOUS TREATMENT AS CLAIMED ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,207,324

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2018258663 ⤷  Start Trial
Australia 2022241509 ⤷  Start Trial
Brazil 112019022280 ⤷  Start Trial
Canada 3060407 ⤷  Start Trial
China 111032082 ⤷  Start Trial
Eurasian Patent Organization 201992573 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.